BACKGROUND: Common genetic polymorphisms at chromosome 3p21.1, including rs2251219 in polybromo 1 (PBRM1), have been implicated in susceptibility to bipolar affective disorder (BP) through genome-wide association studies. Subsequent studies have suggested that this is also a risk locus for other psychiatric phenotypes, including major depression and schizophrenia. METHODS: To replicate the association, we studied 2562 cases with BP and 25,439 control subjects collected from seven cohorts with either genome-wide association or individual genotyping of rs2251219 and tagging single nucleotide polymorphisms across the PBRM1 gene. Results from the different case-control groups were combined with the inverse variance weighting method. RESULTS: In our dataset, rs2251219 was associated with BP (odds ratio [OR] = .89, p = .003), and meta-analysis of previously published data with our nonoverlapping new data confirmed genome-wide significant association (OR = .875, p = 2.68 × 10(-9)). Genotypic data from the SGENE-plus consortium were used to examine the association of the same variant with schizophrenia in an overall sample of 8794 cases and 25,457 control subjects, but this was not statistically significant (OR = .97, p = .21). CONCLUSIONS: There is strong evidence of association of rs2251219 with BP. However, our data do not support association of this marker with schizophrenia. Because the region of association has high linkage disequilibrium, forming a large haplotype block across many genes, it is not clear which gene is causally implicated in the disorder.
BACKGROUND: Common genetic polymorphisms at chromosome 3p21.1, including rs2251219 in polybromo 1 (PBRM1), have been implicated in susceptibility to bipolar affective disorder (BP) through genome-wide association studies. Subsequent studies have suggested that this is also a risk locus for other psychiatric phenotypes, including major depression and schizophrenia. METHODS: To replicate the association, we studied 2562 cases with BP and 25,439 control subjects collected from seven cohorts with either genome-wide association or individual genotyping of rs2251219 and tagging single nucleotide polymorphisms across the PBRM1 gene. Results from the different case-control groups were combined with the inverse variance weighting method. RESULTS: In our dataset, rs2251219 was associated with BP (odds ratio [OR] = .89, p = .003), and meta-analysis of previously published data with our nonoverlapping new data confirmed genome-wide significant association (OR = .875, p = 2.68 × 10(-9)). Genotypic data from the SGENE-plus consortium were used to examine the association of the same variant with schizophrenia in an overall sample of 8794 cases and 25,457 control subjects, but this was not statistically significant (OR = .97, p = .21). CONCLUSIONS: There is strong evidence of association of rs2251219 with BP. However, our data do not support association of this marker with schizophrenia. Because the region of association has high linkage disequilibrium, forming a large haplotype block across many genes, it is not clear which gene is causally implicated in the disorder.
Authors: Hong Chang; Lingyi Li; Tao Peng; Maria Grigoroiu-Serbanescu; Sarah E Bergen; Mikael Landén; Christina M Hultman; Andreas J Forstner; Jana Strohmaier; Julian Hecker; Thomas G Schulze; Bertram Müller-Myhsok; Andreas Reif; Philip B Mitchell; Nicholas G Martin; Sven Cichon; Markus M Nöthen; Stéphane Jamain; Marion Leboyer; Frank Bellivier; Bruno Etain; Jean-Pierre Kahn; Chantal Henry; Marcella Rietschel; Xiao Xiao; Ming Li Journal: Mol Neurobiol Date: 2016-08-25 Impact factor: 5.590
Authors: Ming Li; Xiong-jian Luo; Mikael Landén; Sarah E Bergen; Christina M Hultman; Xiao Li; Wen Zhang; Yong-Gang Yao; Chen Zhang; Jiewei Liu; Manuel Mattheisen; Sven Cichon; Thomas W Mühleisen; Franziska A Degenhardt; Markus M Nöthen; Thomas G Schulze; Maria Grigoroiu-Serbanescu; Hao Li; Chris K Fuller; Chunhui Chen; Qi Dong; Chuansheng Chen; Stéphane Jamain; Marion Leboyer; Frank Bellivier; Bruno Etain; Jean-Pierre Kahn; Chantal Henry; Martin Preisig; Zoltán Kutalik; Enrique Castelao; Adam Wright; Philip B Mitchell; Janice M Fullerton; Peter R Schofield; Grant W Montgomery; Sarah E Medland; Scott D Gordon; Nicholas G Martin; Marcella Rietschel; Chunyu Liu; Joel E Kleinman; Thomas M Hyde; Daniel R Weinberger; Bing Su Journal: Br J Psychiatry Date: 2015-09-03 Impact factor: 9.319
Authors: S Steinberg; S de Jong; M Mattheisen; J Costas; D Demontis; S Jamain; O P H Pietiläinen; K Lin; S Papiol; J Huttenlocher; E Sigurdsson; E Vassos; I Giegling; R Breuer; G Fraser; N Walker; I Melle; S Djurovic; I Agartz; A Tuulio-Henriksson; J Suvisaari; J Lönnqvist; T Paunio; L Olsen; T Hansen; A Ingason; M Pirinen; E Strengman; D M Hougaard; T Orntoft; M Didriksen; M V Hollegaard; M Nordentoft; L Abramova; V Kaleda; M Arrojo; J Sanjuán; C Arango; B Etain; F Bellivier; A Méary; F Schürhoff; A Szoke; M Ribolsi; V Magni; A Siracusano; S Sperling; M Rossner; C Christiansen; L A Kiemeney; B Franke; L H van den Berg; J Veldink; S Curran; P Bolton; M Poot; W Staal; K Rehnstrom; H Kilpinen; C M Freitag; J Meyer; P Magnusson; E Saemundsen; I Martsenkovsky; I Bikshaieva; I Martsenkovska; O Vashchenko; M Raleva; K Paketchieva; B Stefanovski; N Durmishi; M Pejovic Milovancevic; D Lecic Tosevski; T Silagadze; N Naneishvili; N Mikeladze; S Surguladze; J B Vincent; A Farmer; P B Mitchell; A Wright; P R Schofield; J M Fullerton; G W Montgomery; N G Martin; I A Rubino; R van Winkel; G Kenis; M De Hert; J M Réthelyi; I Bitter; L Terenius; E G Jönsson; S Bakker; J van Os; A Jablensky; M Leboyer; E Bramon; J Powell; R Murray; A Corvin; M Gill; D Morris; F A O'Neill; K Kendler; B Riley; N Craddock; M J Owen; M C O'Donovan; U Thorsteinsdottir; A Kong; H Ehrenreich; A Carracedo; V Golimbet; O A Andreassen; A D Børglum; O Mors; P B Mortensen; T Werge; R A Ophoff; M M Nöthen; M Rietschel; S Cichon; M Ruggeri; S Tosato; A Palotie; D St Clair; D Rujescu; D A Collier; H Stefansson; K Stefansson Journal: Mol Psychiatry Date: 2012-11-20 Impact factor: 15.992
Authors: Stephanie H Witt; Wolfgang H Sommer; Anita C Hansson; Carsten Sticht; Marcella Rietschel; Christian C Witt Journal: In Silico Pharmacol Date: 2013-11-13
Authors: Seenae Eum; S Kristian Hill; Ney Alliey-Rodriguez; James M Stevenson; Leah H Rubin; Adam M Lee; Lauren J Mills; James L Reilly; Rebekka Lencer; Sarah K Keedy; Elena Ivleva; Richard S E Keefe; Godfrey D Pearlson; Brett A Clementz; Carol A Tamminga; Matcheri S Keshavan; Elliot S Gershon; John A Sweeney; Jeffrey R Bishop Journal: Neuropsychopharmacology Date: 2021-06-18 Impact factor: 8.294
Authors: Mirko Manchia; Jeffrey Cullis; Gustavo Turecki; Guy A Rouleau; Rudolf Uher; Martin Alda Journal: PLoS One Date: 2013-10-11 Impact factor: 3.240
Authors: Tue Fryland; Jane H Christensen; Jonatan Pallesen; Manuel Mattheisen; Johan Palmfeldt; Mads Bak; Jakob Grove; Ditte Demontis; Jenny Blechingberg; Hong Sain Ooi; Mette Nyegaard; Mads E Hauberg; Niels Tommerup; Niels Gregersen; Ole Mors; Thomas J Corydon; Anders L Nielsen; Anders D Børglum Journal: Genome Med Date: 2016-05-03 Impact factor: 11.117
Authors: Hélène Choquet; Jie Yin; Alice S Jacobson; Brandon H Horton; Thomas J Hoffmann; Eric Jorgenson; Andrew L Avins; Alice R Pressman Journal: Commun Biol Date: 2021-07-22